Prostate Cancer Screening: A Growing Concern in Thailand
Understanding the impact of prostate cancer screening on survival rates in Thailand.
Christian S. Alvarez, Alison M. Mondul, Laura S. Rozek, Hutcha Sriplung, Rafael Meza, Jihyoun Jeon
― 7 min read
Table of Contents
- Screening: The Double-Edged Sword
- Data Sources: Where the Numbers Come From
- Screening Scenarios: What Could Happen?
- Projecting Prostate Cancer Cases
- Projecting Deaths from Prostate Cancer
- The Numbers Game: Deaths Under Different Scenarios
- Shifting Stage Distribution
- Impact of Screening on Prostate Cancer Incidence
- Case Fatality Ratios: Breaking It Down
- Real-World Implications
- Prostate Cancer Screening in Asia
- Strengths and Limitations of the Study
- Conclusion: The Way Forward
- Original Source
Prostate Cancer is becoming a big issue in many countries, and Thailand is no exception. In fact, in the last few decades, the number of people diagnosed with prostate cancer and those who die from it has significantly increased. In Songkhla province, a staggering 75% of prostate cancer cases are diagnosed at an advanced stage, meaning many men are facing tough battles right from the start.
Now, if we hop over to the United States, the situation looks quite different. Most cases there are caught early, thanks in part to a simple blood test known as the PSA test. The good news is that recent guidelines in the US have encouraged more people to get this test done. But does that mean Screening for prostate cancer is a clear win? That’s where it gets a bit tricky.
Screening: The Double-Edged Sword
Screening for prostate cancer raises an interesting debate. On one hand, it can help catch cancer early; on the other, it can lead to unnecessary worry and treatment for cancers that may never have caused any problems. Two major studies tried to figure this out, but the results were mixed. One study from Europe showed that screening could reduce deaths from prostate cancer, while another from the US found no significant difference. The difference in results has puzzled many experts.
So while the idea of catching cancer early sounds good, we also need to be careful. Screening can sometimes lead to finding cancers that may not need treatment, which can cause more harm than good. Still, there's a clear need for early detection, especially in places like Thailand where prostate cancer rates are on the rise.
Data Sources: Where the Numbers Come From
To understand the situation in Thailand better, experts used information from the Songkhla Cancer Registry, which keeps track of cancer cases and deaths. Over a period of 24 years, this registry documented nearly 1,000 prostate cancer cases. The Mortality Rate during this time was about 61.9%. This statistic is alarming, especially since so many cases were diagnosed late.
The researchers also pulled population data from national resources to get a clearer picture of how many men could be affected. They looked specifically at men in Songkhla born in 1960, who are now in their 60s.
Screening Scenarios: What Could Happen?
In their analysis, experts wanted to see what might happen if different rates of screening were used. They considered three different scenarios: 100% of men getting screened, 60% getting screened, and just 15%. To put that in perspective, about 60% of older men in the US have had the PSA test, while Japan reports a much lower rate.
The researchers wanted to follow this group of men as they aged from 50 to 70, a critical period when prostate cancer risks increase.
Projecting Prostate Cancer Cases
To predict how many men might be diagnosed with prostate cancer under different screening scenarios, researchers used existing data to create models. They started with the usual rate of prostate cancer and then adjusted those numbers based on what they knew from other studies about how screening affects detection rates.
The outcome? Higher screening rates could mean a lot more cases of cancer being diagnosed-especially at earlier stages when treatment is likely to be more effective.
Projecting Deaths from Prostate Cancer
Now let’s talk about the scary part: deaths from prostate cancer. To project these numbers, experts used survival models to look at how long men with different types of prostate cancer were expected to live. Since the registry didn’t have specific mortality data, they assumed that if a man died from prostate cancer, it was likely the cancer that caused it.
The researchers made estimates based on statistics from the US, assuming the care available to Thai men would be similar.
The Numbers Game: Deaths Under Different Scenarios
As you can expect, screening can significantly change the numbers on prostate cancer deaths. With no screening at all, the projected number of deaths was 2,155. But if everyone got screened, that number could drop to just 387! That’s a huge difference and shows how screening could potentially save lives.
The stage at which the cancer is found makes all the difference. For instance, if a man is diagnosed early, he stands a better chance of survival than if he finds out he has late-stage cancer.
Shifting Stage Distribution
The data revealed a shift in the type of prostate cancer diagnosed. With higher screening rates, more men were likely to be diagnosed with localized (early-stage) cancer, which is treatable. For example, with no screening, about 4,046 men might be diagnosed with advanced (distant stage) cancer, compared to only 96 under a full screening program.
Visualizing this shift shows how important screening is. Men diagnosed with prostate cancer could have far better outcomes if they can catch it early enough.
Impact of Screening on Prostate Cancer Incidence
In the projected cohort, the number of prostate cancer cases surged as men hit 70 years old. If everyone was screened, they predicted an extra 558 cases at that age. This just shows how PSA testing can lead to more Diagnoses, but also to more worry about cancer.
As for deaths, increased screening significantly decreased the number of expected deaths. For those who got screened 100%, around 1,769 deaths could be prevented, which is a tremendous benefit.
Case Fatality Ratios: Breaking It Down
To gauge how effective screening is, experts calculated what’s known as the case fatality ratio (CFR), which looks at how many diagnosed cases actually lead to death. Under no screening, the CFR was about 0.42, but it dropped to 0.15 with 60% screening and all the way down to 0.05 with full screening.
What this shows is that more screening tends to mean fewer deaths from prostate cancer, which is the goal of any health initiative.
Real-World Implications
While these results sound promising, they are based on models and assumptions. There are many factors to consider when thinking about implementing a screening program. One big factor is whether there are enough resources in place to treat the increased number of cases that would be detected.
Another issue is that cultural attitudes can play a role. Many men may feel embarrassed discussing health issues, particularly urinary problems. This can lead to fewer men seeking screening, even when it’s available.
Prostate Cancer Screening in Asia
While the conversation around prostate cancer screening has started in parts of Asia, there are still no official guidelines in most countries-except for Japan. In Japan, the focus is on PSA screening, as they realize its importance. Other countries in Asia are still in the early stages of determining the best screening practices.
Strengths and Limitations of the Study
One major strength of the study was its simplicity. By using clear models, the researchers made it easier for healthcare authorities to understand potential outcomes. They also used data from the Songkhla Cancer Registry, which provides a solid foundation for their predictions.
However, there are limitations to consider. For instance, using all-cause mortality as a stand-in for prostate cancer death could lead to underestimations of survival rates. Plus, since the data largely comes from the US, it might not be fully applicable to the Thai population due to differences in healthcare access and treatment.
Conclusion: The Way Forward
In the end, screening for prostate cancer in Thailand could have a major impact. It could lead to earlier diagnoses and decrease the number of deaths caused by this disease. However, it’s important to approach this initiative carefully and consider the resources available for treatment, as well as cultural barriers that may affect participation in screening.
In summary, the evidence suggests that a structured screening program could be very beneficial. But like any health initiative, it requires careful planning and understanding of the community's needs and concerns. So, let’s just say, men in Thailand might want to start getting comfortable chatting about their prostate health-it could save their lives!
Title: Potential impact of a population-based screening program on the increased burden of prostate cancer in Thailand: A simulation study
Abstract: BackgroundProstate cancer incidence and mortality are expected to increase considerably in the near future in Thailand. There is thus an urgent need to establish prevention measures, such as screening, to reduce the increasing burden of prostate cancer in Thailand. MethodsUsing data from several sources including the Songkhla Cancer Registry and the census data from Thailand, we conducted a simulation analysis to assess the potential impact of screening on the incidence and mortality of prostate cancer among 10 million males aged 50 to 70 of 1960 birth cohort from Songkhla, Thailand. We assumed 4 different scenarios, including no screening, 15%, 60% and 100% screening uptakes of the prostate-specific antigen test. Furthermore, stage distribution of prostate cancer was assumed based on two major prostate cancer screening trials: European Randomized Study of Screening for Prostate Cancer (ERSPC) and Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. The number of prostate cancer cases was projected using an age-period-cohort model approach, accounting for the expected excess of cases due to screening. Deaths from prostate cancer were then projected using survival probabilities from Songkhla and the United States. Case fatality ratios (CFRs) were also computed. ResultsProstate cancer incidence increased with screening, as expected, with a shift of the stage distribution toward earlier stages, but mortality from prostate cancer decreased with higher screening uptake. Assuming 1.71 excess risk of cases due to screening and stage distribution from the ERSPC trial, we projected an increase of over 7,000 localized cases under 100% screening uptake, while the cases in advanced stages decreased from 4,046 (no screening) to 96 under 100% screening uptake. The number of deaths were reduced by 82% under 100% screening uptake compared to no screening. The CFR also decreased from 0.42 (no screening) to 0.05 (100% screening). ConclusionScreening for prostate cancer could substantially reduce the number of prostate cancer cases in advanced stages and prostate cancer deaths. Although the net benefit depends on the assumed survival rates under screening, which could vary depending on the quality of the implementation, screening would contribute to reducing the escalating burden of prostate cancer in Thai population.
Authors: Christian S. Alvarez, Alison M. Mondul, Laura S. Rozek, Hutcha Sriplung, Rafael Meza, Jihyoun Jeon
Last Update: 2024-11-04 00:00:00
Language: English
Source URL: https://www.medrxiv.org/content/10.1101/2024.10.29.24316321
Source PDF: https://www.medrxiv.org/content/10.1101/2024.10.29.24316321.full.pdf
Licence: https://creativecommons.org/licenses/by/4.0/
Changes: This summary was created with assistance from AI and may have inaccuracies. For accurate information, please refer to the original source documents linked here.
Thank you to medrxiv for use of its open access interoperability.